Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 23;12:693–709. doi: 10.2147/CEOR.S274951

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Lee et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

EORTC QLQ-C30 during BCG treatment.*^#.

Notes: *Changes in EORTC QLQ-C30 domain scores of ≥10 points are considered clinically meaningful. ^#The weighted-average of EORTC QLQ-C30 scores was calculated across all studies that reported these data at each of the three time points; due to the small number of studies reporting these data, other selection criteria such as similar study design similarity were not applied. Data from these studies.⁹^,²⁵^,²⁷^,³⁵ Scores range from 0 to 100 with higher scores indicating higher (ie, worse) symptomology for symptom domains and a higher (ie, better) level of function for functional domains.

Abbreviations: BCG, Bacillus Calmette-Guerin; EORTC QLQ-C30, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire non-muscle invasive bladder cancer 24; GHS, global health status; T0, baseline; T1, end of induction; T2, maintenance.